Fluticasone Furoate
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Fluticasone Furoate: From Corticosteroid Therapy to Atopic Eczema
One-Sentence Summary
Fluticasone Furoate is a potent inhaled/intranasal corticosteroid; the evidence pack does not contain a structured original-indication record for this product (unmarketed in Norway), but it is broadly known as an ICS used for asthma and allergic rhinitis. The TxGNN model predicts it may be effective for Atopic Eczema, with 10 clinical trials and 2 publications currently supporting this direction — though most trials use the Propionate ester rather than Furoate itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (no Norway license records); generically known as an ICS for asthma/allergic rhinitis |
| Predicted New Indication | Atopic Eczema |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L3 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data (original_moa) is not available in the evidence pack. Based on the repurposing rationale, Fluticasone Furoate is described as a high-potency glucocorticoid receptor agonist that suppresses pro-inflammatory cytokines (IL-4, IL-13, TNF-α) and keratinocyte inflammatory responses — the standard mechanism by which topical corticosteroids control atopic dermatitis.
The predicted link to atopic eczema is mechanistically plausible: corticosteroid receptor activation to suppress Th2-driven inflammation is a well-established therapeutic principle across allergic/inflammatory skin conditions. However, nearly all supporting clinical trials in this evidence pack use Fluticasone Propionate, not Fluticasone Furoate. The two are different ester forms with different systemic bioavailability (Furoate has lower systemic exposure), so mechanistic extrapolation is reasonable but not a direct molecular equivalence — this is an important caveat rather than confirmed cross-ester efficacy.
Note: a related predicted indication in the same evidence pack, bronchitis/COPD (rank 2), has direct Furoate-specific RCT evidence (PMID 21977941) and is already a labeled use in combination products (e.g., fluticasone furoate/vilanterol) — that pathway represents label-extension rather than a novel repurposing hypothesis, and carries stronger (L2) evidence than the atopic eczema signal discussed here.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00690105 | Phase 4 | Completed | 577 | Tacrolimus 0.1% vs Fluticasone (Propionate) 0.005% ointment in adults with facial "red face" atopic dermatitis |
| NCT00689832 | Phase 4 | Completed | 487 | Tacrolimus 0.03% vs Fluticasone 0.005% ointment in children ≥2y with moderate-severe AD |
| NCT03742414 | Phase 2 | Active, not recruiting | 398 | Proactive skin-barrier care + fluticasone propionate cream vs reactive therapy to prevent AD/food allergy progression in infants |
| NCT01915914 | Phase 4 | Completed | 107 | Intermittent (2x/week) fluticasone propionate 0.05% cream + moisturizer to reduce AD relapse risk in stabilized pediatric patients |
| NCT00616538 | Phase 4 | Completed | 121 | EpiCeram (non-steroidal) vs mid-strength fluticasone propionate 0.05% in pediatric moderate-severe AD |
| NCT04706559 | NA | Completed | 98 | Oral probiotic supplementation efficacy in children with AD (SCORAD index) — adjunctive, not steroid-focused |
| NCT00119158 | Phase 4 | Completed | 90 | Concomitant Elidel (pimecrolimus) 1% + Cutivate (fluticasone propionate) 0.05% in severe AD lesions |
| NCT00546000 | Phase 4 | Completed | 56 | Open-label HPA-axis safety evaluation of Cutivate (fluticasone propionate) lotion 0.05% in pediatric AD |
| NCT01772056 | Phase 3 | Terminated | 54 | Twice-weekly fluticasone propionate 0.05% maintenance to reduce AD relapse in children — trial terminated early |
| NCT07537751 | NA | Completed | 40 | Topical crisaborole 2% vs fluticasone propionate 0.05% in mild-moderate pediatric AD (SCORAD/ISGA outcomes) |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 19571596 | 2009 | Review | Neuroimmunomodulation | Reviews intranasal corticosteroid use across allergic rhinitis, asthma and atopic dermatitis, with focus on HPA-axis suppression risk |
| 40066386 | 2025 | Case Report | Indian J Otolaryngol Head Neck Surg | Case study on allergen immunotherapy in autoimmune patients; notes AIT application extends to atopic dermatitis |
Norway Market Information
Currently no Norway market authorizations found for this product (market_status: Not Marketed, 0 licenses on record).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for Fluticasone Furoate specifically in atopic eczema is Level L3 (observational/uncontrolled and cross-ester extrapolation) — nearly all supporting trials use the Propionate ester, and the only Phase 3 RCT (NCT01772056) was terminated early with a small sample (n=54). The mechanism is plausible but not yet confirmed for the Furoate ester in this indication.
To proceed, the following is needed:
- TFDA/Norway package insert warnings and contraindications (currently a Blocking data gap — required before any S1 safety evaluation)
- Confirmed mechanism of action (MOA) data specific to Fluticasone Furoate (High-severity data gap)
- Direct Furoate-specific trial or pharmacokinetic bridging data for atopic dermatitis (most existing evidence is for Propionate)
- Consider prioritizing the bronchitis/COPD signal (rank 2) instead, which has direct Furoate RCT evidence (PMID 21977941) and L2 evidence supporting "Proceed with Guardrails"
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.